Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping a phase ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Tirzepatide is an active ingredient of Eli Lilly’s popular Zepbound and Mounjaro. The trial was designed to evaluate the ...
Lilly announces a $3B expansion in Wisconsin to boost production of weight loss drugs and strengthen its position in the ...
In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...
Eli Lilly and Novo Nordisk continue to ramp production facilities and capacity for booming weight-loss drugs like Wegovy and ...
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
We recently compiled a list of the 10 Dividend Knights that Beat The Market Last 3 Years. In this article, we are going to ...
A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s ...
To receive the full newsletter in your inbox for free sign up here) An experimental immunotherapy drug is a potentially effective treatment for patients with bladder cancer who no longer respond to ...
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...